Amgen Inc.
HealthcareNASDAQ:AMGN · NASDAQ Global Select
-$0.45 today
Vol 1.16M · Avg 2.67M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $12.0B |
| Receivables | $9.1B |
| Inventory | $6.2B |
| Other Current | $4.1B |
| Total Current Assets | $31.5B |
| PP&E (Net) | $8.2B |
| Goodwill | $18.7B |
| Intangible Assets | $21.4B |
| Other Non-current | $12.8B |
| Total Non-current Assets | $61.0B |
| Total Assets | $92.5B |
Analysis
Selected assets total $92.5B for Latest. The largest visible component is Intangible Assets at $21.4B, about 23.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.1B -23.8% | $12.0B +9.4% | $10.9B +43.5% | $7.6B -4.5% | $8.0B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 -100.0% | $1.7B +3391.7% | $48.0M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $9.6B +27.6% | $7.5B -5.6% | $7.9B +24.2% | $6.4B +9.5% | $5.8B | $533.8M | $399.4M | -$1.7B |
| Inventory | $6.2B -11.0% | $7.0B -26.5% | $9.5B +93.1% | $4.9B +20.7% | $4.1B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $4.1B +886.4% | $419.0M +49.1% | $281.0M -20.8% | $355.0M +77.5% | $200.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $29.1B +0.1% | $29.0B -4.3% | $30.3B +36.7% | $22.2B +14.4% | $19.4B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $7.9B +20.9% | $6.5B +10.1% | $5.9B +9.5% | $5.4B +4.7% | $5.2B | $1.2B | $1.5B | $687.8M |
| Goodwill | $18.7B +0.2% | $18.6B +0.0% | $18.6B +20.0% | $15.5B +4.3% | $14.9B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $22.3B -19.6% | $27.7B -15.1% | $32.6B +103.0% | $16.1B +5.9% | $15.2B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 -100.0% | $5.4B +13.7% | $4.7B | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $12.7B +176.7% | $4.6B -6.6% | $4.9B -16.9% | $5.9B -9.6% | $6.5B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $61.5B -2.0% | $62.8B -6.0% | $66.8B +55.6% | $42.9B +2.8% | $41.8B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $90.6B -1.4% | $91.8B -5.5% | $97.2B +49.2% | $65.1B +6.5% | $61.2B | $13.3B | $11.9B | $10.6B |
| Account Payables | $20.9B +994.9% | $1.9B +20.0% | $1.6B +1.1% | $1.6B +15.1% | $1.4B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $4.6B +29.5% | $3.5B +146.0% | $1.4B -9.3% | $1.6B +1728.7% | $87.0M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 -100.0% | $1.7B +39.2% | $1.2B +70.5% | $701.0M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $0 -100.0% | $1.3B -3.8% | $1.4B +25.7% | $1.1B -32.3% | $1.6B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $25.5B +10.3% | $23.1B +25.6% | $18.4B +17.2% | $15.7B +28.8% | $12.2B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $50.0B -11.6% | $56.5B -10.5% | $63.2B +69.1% | $37.4B +12.4% | $33.2B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $1.4B -15.5% | $1.6B -31.4% | $2.4B +21300.0% | $11.0M | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $5.1B +7.9% | $4.7B -32.9% | $7.0B -16.7% | $8.4B -7.2% | $9.1B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $56.4B -10.2% | $62.9B -13.3% | $72.5B +58.5% | $45.8B +8.3% | $42.3B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $81.9B -4.7% | $86.0B -5.5% | $90.9B +47.9% | $61.5B +12.8% | $54.5B | $14.7B | $3.7B | $9.6B |
| Common Stock | $8.7B -74.2% | $33.5B +1.4% | $33.1B +1.7% | $32.5B +1.3% | $32.1B | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $0 +100.0% | -$27.6B -3.9% | -$26.5B +7.2% | -$28.6B -16.3% | -$24.6B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 +100.0% | -$66.0M +77.2% | -$289.0M -25.1% | -$231.0M +71.0% | -$796.0M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $8.7B +47.3% | $5.9B -5.7% | $6.2B +70.2% | $3.7B -45.4% | $6.7B | $9.1B | $7.7B | $3.3B |
| Total Debt | $54.6B -9.1% | $60.1B -7.0% | $64.6B +65.9% | $38.9B +16.9% | $33.3B | $724.2M | $410.6M | $399.4M |
| Net Debt | $45.5B -5.5% | $48.1B -10.3% | $53.7B +71.4% | $31.3B +23.7% | $25.3B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$296.18B
Novartis AG
NYSE:NVS
$292.74B
Novo Nordisk A/S
NYSE:NVO
$196.77B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.57B
Pfizer Inc.
NYSE:PFE
$149.27B
Danaher Corporation
NYSE:DHR
$127.55B
Bristol-Myers Squibb Company
NYSE:BMY
$116.63B
GSK plc
NYSE:GSK
$106.58B
Sanofi
NASDAQ:SNY
$106.44B
Boston Scientific Corporation
NYSE:BSX
$69.90B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does AMGN have?
Amgen Inc. (AMGN) reported $9.13B in cash and equivalents in fiscal 2025.
How much debt does AMGN carry?
Amgen Inc. (AMGN) reported $54.60B of total debt, with net debt of $45.48B.
Explore More
Continue the stock analysis
Jump to another research area for this company.